Sector News

Shareholder asks Amgen to split into two businesses

October 22, 2014
Life sciences
Amgen is keeping its own counsel after one major investors, hedge fund Third Point, urged the biotech to consider splitting into two separate businesses.
 
High-profile activist investor and Third Point founder Daniel Loeb sent out a letter to backers about Amgen, claiming that the fund is now “one of the company’s largest shareholders”. He wrote that “the obscured fundamental value and investor scepticism that have led to Amgen’s valuation discount can be easily unlocked, saying the biotech needs to focus its R&D efforts and reduce “a bloated cost structure”.
 
Aside from this, however, Mr Loeb is in favour of “a more radical” approach, namely splitting the company in two, one being Amgen’s “assets–cash‐generative mature products and the other an “R&D‐intensive growth products” unit.
 
The letter says Amgen stock could get to $189 a share by the end of 2016 and $218 by the end of 2017 if the company cuts costs and makes R&D more efficient. However, with a split, Third Point believes it could be worth $249 a share in two years; Amgen ended the day up 4.8% after the hedge fund report at $144.09.
 
Board described as ‘open-minded’ by Loeb
 
Mr Loeb was not making an aggressive attack and praised Amgen for taking some steps to cut costs, describing the board as being “open‐minded and receptive to our ideas”. Still, “we firmly believe that the company is at an inflection point,” he wrote, and “we hope to maintain our constructive dialogue with management as the company moves towards closing its valuation gap”.
 
Amgen quickly released a statement “with respect to media inquiries concerning Third Point equity position in Amgen”, saying it has “always appreciated the perspectives of all of its shareholders, including Third Point, and welcomes constructive input toward our common goal of enhancing shareholder value”.
 
The firm added that the board “frequently receives input from shareholders, including ideas like those offered by Third Point” and “continually assess Amgen’s strategic priorities – and, when appropriate, take action”. More on Amgen’s “strategic priorities and update on our restructuring plans” will be laid out “at our business review on October 28”.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend